Bristol-Myers key studies still have high chance of success, says JPMorgan JPMorgan says it still sees a high probability that Bristol-Myers' two key phase III studies of nivolumab in 2nd-line lung cancer hit their endpoints. The firm views the study results as the key catalyst for shares in the next six months, and notes its view is unchanged following this year's American Society of Clinical Oncology meeting. JPMorgan has an Overweight rating on Bristol with a $60 price target.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.